CD44 and neoplasm: Tumor derived from CD44− C3A-iCSCs also displayed well-differentiated tumor cells compared to CD44+ C3A-iCSCs, which suggested CD44− C3A-iCSCs derived tumor cells exhibited lower malignant degree.